Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialJ. Clin. Oncol 2023 Feb 13;[EPub Ahead of Print], PA Ascierto, EJ Lipson, R Dummer, J Larkin, GV Long, RE Sanborn, V Chiarion-Sileni, B Dréno, S Dalle, D Schadendorf, MK Callahan, M Nyakas, V Atkinson, CA Gomez-Roca, N Yamazaki, HA Tawbi, N Sarkis, D Warad, S Dolfi, P Mitra, S Suryawanshi, JJ Grob
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.